- The immune checkpoint CD96 defines a distinct lymphocyte phenotype & is highly expressed on tumor-infiltrating T cells. [Journal Article]
- ICImmunol Cell Biol 2018 Sep 17
- CD96 has recently been shown to be a potent immune checkpoint molecule in mice but a similar role in humans is unknown. In this study we provide a detailed map of CD96 expression across human lymphoc...
CD96 has recently been shown to be a potent immune checkpoint molecule in mice but a similar role in humans is unknown. In this study we provide a detailed map of CD96 expression across human lymphocyte lineages, the kinetics of CD96 regulation upon T cell activation and co-expression with other conventional and emerging immune checkpoint molecules. We show that CD96 is predominantly expressed by T cells and has a unique lymphocyte expression profile. CD96high T cells exhibited distinct effector functions upon activation. Of note, CD96 expression highly correlated with T cell markers in primary and metastatic human tumors and was elevated on antigen-experienced T cells and tumor infiltrating lymphocytes. Collectively, these data demonstrate that CD96 may be a promising immune checkpoint to enhance T cell function against human cancer and infectious disease. This article is protected by copyright. All rights reserved.
- Role of secretory clusterin in hepatocarcinogenesis. [Review]
- TGTransl Gastroenterol Hepatol 2018; 3:48
- Secretory clusterin (sCLU) is a small stress-induced cytoprotective chaperone protein. Its biological functions are similar to those of a heat-shock protein. The sCLU plays a crucial role in cell pro...
Secretory clusterin (sCLU) is a small stress-induced cytoprotective chaperone protein. Its biological functions are similar to those of a heat-shock protein. The sCLU plays a crucial role in cell proliferation, multiple drug resistance, metastasis, and tumor progression. Abnormal sCLU expression in tumor tissues or sera of patients with primary hepatic cancer has been considered a useful biomarker for diagnosis and surveillance. However, the exact relationship between sCLU overexpression and malignant transformation of hepatocytes is still unknown. The present review examines some novel advances of the knowledge about the oncogenic role of sCLU in hepatocarcinogenesis.
- Adjuvant radiation for T1-2N1 oral cavity cancer survival outcomes and utilization treatment trends: Analysis of the SEER database. [Journal Article]
- OOOral Oncol 2018; 85:1-7
- CONCLUSIONS: Adjuvant radiation therapy is independently associated with a significant survival benefit for patients with both T1N1 and T2N1 OCSCC. However, this study demonstrates that patients with T1N1 cancer are less likely to receive adjuvant radiation and utilization is decreasing.
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. [Journal Article]
- LOLancet Oncol 2018 Sep 12
- CONCLUSIONS: The combination of encorafenib plus binimetinib provided clinically meaningful efficacy with good tolerability as shown by improvements in both progression-free survival and overall survival compared with vemurafenib. These data suggest that the combination of encorafenib plus binimetinib is likely to become an important therapeutic option in patients with BRAFV600-mutant melanoma.
- Feeling the sound - short-term effect of a vibroacoustic music intervention on well-being and subjectively assessed warmth distribution in cancer patients-A randomized controlled trial. [Journal Article]
- CTComplement Ther Med 2018; 40:171-178
- CONCLUSIONS: Sound-bed intervention improved momentary well-being and caused self-perceived physiological changes associated with relaxation beyond the benefits of simple resting time (control condition). Thus, it might be a promising approach to improve well-being in cancer patients.
- Clinical Relevance of Genomic Changes in Recurrent Pediatric Solid Tumors. [Journal Article]
- TOTransl Oncol 2018 Sep 11; 11(6):1390-1397
- CONCLUSIONS: We characterized genomic changes in recurrent pediatric solid tumors. These findings could help to understand the biology of relapsed childhood cancer and to develop personalized treatment based on their genetic profile.
- Carcinocythemia: A rare entity becoming more common? A 3-year, single institution series of seven cases and literature review. [Journal Article]
- IJInt J Lab Hematol 2018 Sep 14
- CONCLUSIONS: This represents the largest series of carcinocythemia reported. The identification of 7 cases at one institution over a 3-year period suggests carcinocythemia may becoming more common. Raising awareness of this entity and its associated clinicopathologic findings may help avoid diagnostic pitfalls in blood smear examinations and may guide timely clinical management.
- Oncologist Volume and Outcomes in Older Adults Diagnosed With Diffuse Large B Cell Lymphoma. [Journal Article]
- CCancer 2018 Sep 14
- CONCLUSIONS: In older adults diagnosed with DLBCL, receiving care from a provider with more experience treating lymphoma patients was associated with receipt of guideline-adherent therapy, reduced hospitalizations, and improved survival. Clinical volume may be an important factor in providing high-quality cancer care in the modern era.
- Positional integration of lung adenocarcinoma susceptibility loci with primary human alveolar epithelial cell epigenomes. [Journal Article]
- EEpigenomics 2018 Sep 13
- CONCLUSIONS: Integration of candidate LUAD risk SNPS with epigenomic marks from normal alveolar epithelium identified numerous candidate functional LUAD risk SNPs including rs6942067, which appears to affect DCBLD1 expression. Data deposition: Data are provided in GEO record GSE84273.
New Search Next
- Molecular Diagnostics in Clinical Oncology. [Review]
- FMFront Mol Biosci 2018; 5:76
- There are multiple applications of molecular tests in clinical oncology. Mutation analysis is now routinely utilized for the diagnosis of hereditary cancer syndromes. Healthy carriers of cancer-predi...
There are multiple applications of molecular tests in clinical oncology. Mutation analysis is now routinely utilized for the diagnosis of hereditary cancer syndromes. Healthy carriers of cancer-predisposing mutations benefit from tight medical surveillance and various preventive interventions. Cancers caused by germ-line mutations often require significant modification of the treatment strategy. Personalized selection of cancer drugs based on the presence of actionable mutations has become an integral part of cancer therapy. Molecular tests underlie the administration of EGFR, BRAF, ALK, ROS1, PARP inhibitors as well as the use of some other cytotoxic and targeted drugs. Tumors almost always shed their fragments (single cells or their clusters, DNA, RNA, proteins) into various body fluids. So-called liquid biopsy, i.e., the analysis of circulating DNA or some other tumor-derived molecules, holds a great promise for non-invasive monitoring of cancer disease, analysis of drug-sensitizing mutations and early cancer detection. Some tumor- or tissue-specific mutations and expression markers can be efficiently utilized for the diagnosis of cancers of unknown primary origin (CUPs). Systematic cataloging of tumor molecular portraits is likely to uncover a multitude of novel medically relevant DNA- and RNA-based markers.